{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:10:03Z","timestamp":1778260203654,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Atezolizumab is currently the only immunotherapy used in conjunction with nab-paclitaxel for locally advanced or triple negative breast cancer. Limited data is available regarding hemolytic anemia as a side effect of atezolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>\n                      We describe a 59-year-old female with a history of triple negative breast cancer with bone metastases presenting for follow up on Cycle 1, Day 15 of atezolizumab and nab-paclitaxel (100\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). Patient\u2019s complete blood count (CBC) showed macrocytic anemia, with further workup significant for autoimmune hemolytic anemia (AIHA) attributed to atezolizumab. Management and outcome: Patient was started on a high dose prednisone taper starting at 80\u2009mg daily for 16\u2009days, folic acid 1\u2009mg three times daily, iron sucrose, and darbepoetin alfa. Patient\u2019s counts recovered, and she was able to start Cycle 2 and continued through Cycle 10 without any additional pre-medications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Hemolytic anemia induced by atezolizumab is a rare side effect that was successfully treated in this patient with a prednisone taper.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220957720","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T03:22:22Z","timestamp":1600658542000},"page":"1026-1028","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Atezolizumab-induced hemolytic anemia \u2013 A case report"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-3984","authenticated-orcid":false,"given":"Christina M","family":"Younce","sequence":"first","affiliation":[{"name":"Aurora BayCare Medical Center, Green Bay, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica M","family":"Lawton","sequence":"additional","affiliation":[{"name":"Aurora BayCare Medical Center, Green Bay, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhimant R","family":"Patel","sequence":"additional","affiliation":[{"name":"Aurora Cancer Care, Green Bay, USA"},{"name":"School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"bibr1-1078155220957720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"bibr2-1078155220957720","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25448"},{"key":"bibr3-1078155220957720","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13187"},{"key":"bibr4-1078155220957720","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpha.2019.02.012"},{"key":"bibr5-1078155220957720","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr6-1078155220957720","first-page":"84","volume":"2","author":"Ortin X.","year":"2019","journal-title":"J Blood Transfus Dis"},{"key":"bibr7-1078155220957720","doi-asserted-by":"publisher","DOI":"10.1159\/000452296"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220957720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220957720","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220957720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:44Z","timestamp":1777688624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220957720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/1078155220957720"],"URL":"https:\/\/doi.org\/10.1177\/1078155220957720","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}